ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Although the pathway inhibits the activation of AKT, which is a downstream component of BCR-ABL pathway, it also leads to release of inhibitory sequestration of FOXO, which promotes quiescence in CML stem cells, and ultimately results in TKI resistance25, 26.